The IMPACT study had a similar design to the CTONG1104 trial, which compared adjuvant gefitinib with chemotherapy for patients with resected stage II–IIIA NSCLC harboring EGFR mutations [23]. Here, EGFR is linked to non-small cell lung carcinoma.